More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.Learn more
Pediatric Dermatology Efficacy
Taltz is the first IL-17A antagonist approved for the treatment of pediatric patients as young as age 6 with moderate to severe plaque psoriasis (PsO)1
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
SELECT IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.